Recommendations for the clinical use of anti ⁃ Aβ monoclonal antibody for Alzheimer's disease (2024)

Abstract

Several anti‑Aβ monoclonal antibody drugs have been approved for clinical use at home and abroad recently. In order to facilitate its safe and effective treatment of anti‑Aβ monoclonal antibody drugs for Alzheimer's disease (AD) in China, we present recommendations for the clinical use of anti‑Aβ monoclonal antibody drugs based on existing clinical trials and the clinical practice of AD treatment with Aducanumab at Ruijin Hospital Hainan Branch, Shanghai Jiaotong University School of Medicine. The recommendations include clinical indications, pre ‑ medication assessment and preparation, medication instructions and precautions, as well as post ‑ medication clinical monitoring, which is aimed to furnish clinicians with comprehensive medication guidance.

DOI: 10.3969/j.issn.1672‑6731.2024.03.002